What's Happening?
Pop star Lady Gaga, whose real name is Stefani Germanotta, has publicly announced her role on the board of Massachusetts biotech startup Outer Bio. Founded in 2022 by Germanotta and her fiancé Michael Polansky, who serves as CEO, Outer Bio has secured
approximately $23 million in funding from investors including Wing Ventures, Initialized Capital, and Hawktail. The company utilizes a discovery platform called Yuna, which keeps full-thickness human skin alive outside the body for weeks. This platform generates biological data that is then combined with artificial intelligence to identify new compounds for skin health and dermatology. The human skin tissue used by Yuna is surgically discarded material, often from cosmetic procedures, sourced through biobanks like the National Disease Research Interchange and the Cooperative Human Tissue Network, both federally funded by the National Institute of Health (NIH) and the National Cancer Institute. Outer Bio is currently generating revenue through collaborative research partnerships rather than direct product sales.
Why It's Important?
Lady Gaga's involvement in Outer Bio signifies a notable shift of celebrity investment into scientific research, particularly in the biotech sector, moving beyond traditional celebrity endorsements or product lines. This venture could bring significant public attention and potentially more investment to the field of skin longevity and dermatological innovation. The company's Yuna platform, which maintains human skin tissue viability for extended periods, represents a significant advancement in ex vivo research. This capability allows for the study of slower biological processes like collagen remodeling and chronic inflammation, which are crucial for understanding aging and various skin conditions. The use of AI to screen 750 million compounds annually could dramatically accelerate the discovery of new therapeutic and cosmetic ingredients, potentially leading to more effective and targeted treatments for skin health issues. This approach could also reduce the reliance on animal testing, offering a more ethical and human-relevant model for dermatological research.
What's Next?
Outer Bio is currently focused on collaborative research partnerships with pharmaceutical and cosmetics companies, as well as ingredient suppliers, to further develop and commercialize its discoveries. The company has six active development programs, with four candidates considered likely to reach commercialization. While their initial focus is on consumer skincare due to a faster path to market, the Yuna platform is designed to be equally relevant for dermatology and drug development. Outer Bio plans to continue developing through partnerships rather than becoming a drug developer itself. The company has already published a preprint demonstrating Yuna's ability to model chronic inflammation, aging-associated tissue remodeling, and environmental stress, suggesting future research will aim to provide a translational framework for investigating skin tissue dysfunction and evaluating therapeutic interventions. Further announcements regarding specific partnerships are expected in the near future.
Beyond the Headlines
Lady Gaga's entry into the biotech space with Outer Bio highlights a growing trend of high-profile individuals investing in scientific and technological advancements, potentially influencing public perception and trust in scientific research. This move could inspire other celebrities to direct their resources towards impactful scientific endeavors, fostering innovation and addressing complex health challenges. The ethical implications of using surgically discarded human tissue are also noteworthy; while sourced from federally funded biobanks, the practice raises questions about consent, tissue ownership, and the commercialization of human biological materials. However, it also presents an opportunity to utilize materials that would otherwise be discarded, contributing to scientific progress. The integration of AI with biological data in Outer Bio's platform underscores the increasing reliance on advanced computational methods in scientific discovery, pushing the boundaries of what's possible in personalized medicine and targeted therapies for skin health.
